Current and emerging therapies for the treatment of pancreatic cancer

References

• JanesRHJrNiederhuberJEChmielJSNational patterns of care for pancreatic cancer. Results of a survey by the Commission on CancerAnn Surg199622332612728604906
   PubMed Web of Science ®Google Scholar
• CalleEERodriguezCWalker-ThurmondKThunMJOverweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adultsN Engl J Med2003348171625163812711737
   PubMed Web of Science ®Google Scholar
• ShaibYDavilaJNaumannCEl-SeragHThe impact of curative intent surgery on the survival of pancreatic cancer patients: a U.S. Population-based studyAm J Gastroenterol200710271377138217403071
   PubMed Web of Science ®Google Scholar
• BurrisHAIIIMooreMJAndersenJImprovements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialJ Clin Oncol1997156240324139196156
   PubMed Web of Science ®Google Scholar
• KastrinosFMukherjeeBTayobNRisk of pancreatic cancer in families with Lynch syndromeJAMA2009302161790179519861671
   PubMed Web of Science ®Google Scholar
• FerroneCRLevineDATangLHBRCA germline mutations in Jewish patients with pancreatic adenocarcinomaJ Clin Oncol200927343343819064968
   PubMed Web of Science ®Google Scholar
• BaoYMichaudDSPhysical activity and pancreatic cancer risk: a systematic reviewCancer Epidemiol Biomarkers Prev200817102671268218843009
   PubMed Web of Science ®Google Scholar
• MichaudDSGiovannucciEWillettWCColditzGAStampferMJFuchsCSPhysical activity, obesity, height, and the risk of pancreatic cancerJAMA2001286892192911509056
   PubMed Web of Science ®Google Scholar
• LiDMorrisJSLiuJBody mass index and risk, age of onset, and survival in patients with pancreatic cancerJAMA2009301242553256219549972
   PubMed Web of Science ®Google Scholar
• GumbsAAObesity, pancreatitis, and pancreatic cancerObes Surg20081891183118718563497
   PubMed Web of Science ®Google Scholar
• SmeenkHGTranTCErdmannJvan EijckCHJeekelJSurvival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist?Langenbecks Arch Surg200539029410315578211
   PubMed Web of Science ®Google Scholar
• MuDQPengSYWangGFRisk factors influencing recurrence following resection of pancreatic head cancerWorld J Gastroenterol200410690690915040043
   PubMed Web of Science ®Google Scholar
• ShibataKMatsumotoTYadaKSasakiAOhtaMKitanoSFactors predicting recurrence after resection of pancreatic ductal carcinomaPancreas2005311697315968250
   PubMed Web of Science ®Google Scholar
• AbramsRALowyAMO’ReillyEMWolffRAPicozziVJPistersPWCombined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statementAnn Surg Oncol20091671751175619390900
   PubMed Web of Science ®Google Scholar
• KalserMHEllenbergSSPancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resectionArch Surg198512088999034015380
   PubMed Web of Science ®Google Scholar
• KlinkenbijlJHJeekelJSahmoudTAdjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative groupAnn Surg1999230677678210615932
   PubMed Web of Science ®Google Scholar
• GarofaloMCRegineWFTanMTOn statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancerAnn Surg2006244233233316858208
   PubMed Web of Science ®Google Scholar
• NeoptolemosJPStockenDDFriessHfor the European Study Group for Pancreatic CancerA randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancerN Engl J Med2004350121200121015028824
   PubMed Web of Science ®Google Scholar
• ChotiMAdjuvant therapy for pancreatic cancer – the debate continuesN Engl J Med2004350121249125115028829
   PubMed Web of Science ®Google Scholar
• CraneCHBen-JosefESmallWJrChemotherapy for pancreatic cancerN Engl J Med2004350262713271515218575
   PubMed Web of Science ®Google Scholar
• KosugeTKiuchiTMukaiKKakizoeTfor the Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer (JSAP)A multicenter randomized controlled trial to evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in cases of pancreatic cancerJpn J Clin Oncol200636315916516490736
   PubMed Web of Science ®Google Scholar
• OettleHPostSNeuhausPAdjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trialJAMA2007297326727717227978
   PubMed Web of Science ®Google Scholar
• UenoHKosugeTMatsuyamaYA randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic CancerBr J Cancer2009101690891519690548
   PubMed Web of Science ®Google Scholar
• NeoptolemosJBüchlerMStockenDDESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma. ASCO Annual MeetingJ Clin Oncol200927Suppl 18 Abstract LBA4505.
   Web of Science ®Google Scholar
• VaradhacharyGRTammEPAbbruzzeseJLBorderline resectable pancreatic cancer: definitions, management, and role of preoperative therapyAnn Surg Oncol20061381035104616865597
   PubMed Web of Science ®Google Scholar
• UjikiMBTalamontiMSGuidelines for the surgical management of pancreatic adenocarcinomaSemin Oncol200734431132017674959
   PubMed Web of Science ®Google Scholar
• WhiteRRHurwitzHIMorseMANeoadjuvant chemoradiation for localized adenocarcinoma of the pancreasAnn Surg Oncol200181075876511776488
   PubMed Web of Science ®Google Scholar
• AmmoriJBCollettiLMZalupskiMMSurgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreasJ Gastrointest Surg20037676677213129554
   PubMed Web of Science ®Google Scholar
• JessupJMSteeleGJrMayerRJNeoadjuvant therapy for unresectable pancreatic adenocarcinomaArch Surg199312855595648098206
   PubMed Web of Science ®Google Scholar
• PilepichMVMillerHHPreoperative irradiation in carcinoma of the pancreasCancer Biol Ther198046919451949
   Google Scholar
• BrunnerTBGrabenbauerGGBaumUHohenbergerWSauerRAdjuvant and neoadjuvant radiochemotherapy in ductal pancreatic carcinomaStrahlenther Onkol2000176626527310897253
   PubMed Web of Science ®Google Scholar
• WeeseJLNussbaumMLPaulARIncreased resectability of locally advanced pancreatic and periampullary carcinoma with neoadjuvant chemoradiotherapyInt J Pancreatol199071–31771852081923
   PubMedGoogle Scholar
• MassuccoPCapussottiLMagninoAPancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survivalAnn Surg Oncol20061391201120816955382
   PubMed Web of Science ®Google Scholar
• BrownKMSiripurapuVDavidsonMChemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinomaAm J Surg2008195331832118308038
   PubMed Web of Science ®Google Scholar
• WilkowskiRThomaMBrunsCWagnerAHeinemannVChemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancerJOP20067434936016832132
   PubMedGoogle Scholar
• TalamontiMSSmallWJrMulcahyMFA multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinomaAnn Surg Oncol200613215015816418882
   PubMed Web of Science ®Google Scholar
• IokaTTanakaSNakaizumiANishiyamaKA phase I trial of chemoradiation therapy with concurrent full dose gemcitabine for unresectable locally advanced pancreatic adenocarcinomaJ Clin Oncol2005231654209
   Google Scholar
• SmallWJrBJFreedmanGMFull-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trialJ Clin Oncol200826694294718281668
   PubMed Web of Science ®Google Scholar
• RegineWFWinterKAAbramsRAFluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trialJAMA200829991019102618319412
   PubMed Web of Science ®Google Scholar
• LoehrerPJPowellMECardenesHRA randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201J Clin Oncol200826Suppl 20 Abstract 4506.
   Google Scholar
• MartiJLHochesterHSHiotisSPDonahueBRyanTNewmanEPhase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancerAnn Surg Oncol200815123521353118830756
   PubMed Web of Science ®Google Scholar
• ChauffertBMornexFBonnetainFPhase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studyAnn Oncol20081991592159918467316
   PubMed Web of Science ®Google Scholar
• WhiteRRXieHBGottfriedMRSignificance of histological response to preoperative chemoradiotherapy for pancreatic cancerAnn Surg Oncol200512321422115827813
   PubMed Web of Science ®Google Scholar
• PedduPQuagliaAKanePAKaraniJBRole of imaging in the management of pancreatic massCrit Rev Oncol Hematol2009701122318951813
   PubMed Web of Science ®Google Scholar
• TammECharnsangavejCSzklarukJAdvanced 3-D imaging for the evaluation of pancreatic cancer with multidetector CTInt J Gastrointest Cancer2001301–2657112489581
   PubMedGoogle Scholar
• MaiseyNRWebbAFluxGDFDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot studyBr J Cancer200083328729310917540
   PubMed Web of Science ®Google Scholar
• MercadanteSNicosiaFCeliac plexus block: a reappraisalReg Anesth Pain Med199823137489552777
   PubMed Web of Science ®Google Scholar
• SakorafasGHTsiotouAGSarrMGIntraoperative celiac plexus block in the surgical palliation for unresectable pancreatic cancerEur J Surg Oncol199925442743110419716
   PubMed Web of Science ®Google Scholar
• EisenbergECarrDBChalmersTCNeurolytic celiac plexus block for treatment of cancer pain: A meta-analysisAnesth Analg1995822902957818115
   PubMed Web of Science ®Google Scholar
• LillemoeKDCameronJLKaufmanHSChemical splanchnicectomy in patients with unresectable pancreatic cancer: a prospective randomized trialAnn Surg199321754474557683868
   PubMed Web of Science ®Google Scholar
• MatsumotoJTraversoLWExocrine function following the whipple operation as assessed by stool elastaseJ Gastrointest Surg20061091225122917114009
   PubMed Web of Science ®Google Scholar
• PerezMMNewcomerADMoertelCGGoVLDimagnoEPAssessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancerCancer19835223463526305473
   PubMed Web of Science ®Google Scholar
• BrunoMJHaverkortEBTijssenGPPlacebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head regionGut19984292969505892
   PubMed Web of Science ®Google Scholar
• BachmannJKettererKMarschCPancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary functionBMC Cancer200928925519635171
   PubMedGoogle Scholar
• RobinsonDWJrEisenbergDFCellaDZhaoNde BoerCDeWitteMThe prognostic significance of patient-reported outcomes in pancreatic cancer cachexiaJ Support Oncol20086628329018724539
   PubMedGoogle Scholar
• HeiskanenTMatzkeSHaakanaSGergovMVuoriEKalsoETransdermal fentanyl in cachectic cancer patientsPain20091441–221822219442446
   PubMed Web of Science ®Google Scholar
• MannCDThomassetSCJohnsonNACombined biliary and gastric bypass procedures as effective palliation for unresectable malignant diseaseANZ J Surg200979647147519566872
   PubMed Web of Science ®Google Scholar
• CanBSarayACaglikulekçiMSaranYEffects of obstructive jaundice on the peripheral nerve: an ultrastructural study in ratsEur Surg Res200436422623315263828
   PubMed Web of Science ®Google Scholar
• CostamagnaGPandolfiMEndoscopic stenting for biliary and pancreatic malignanciesJ Clin Gastroenterol200438596714679329
   PubMed Web of Science ®Google Scholar
• BallingerABMcHughMCatnachSMSymptom relief and quality of life after stenting for malignant bile duct obstructionGut1994354674707513672
   PubMed Web of Science ®Google Scholar
• TibbleJACairnsSRRole of endoscopic endoprostheses in proximal malignant biliary obstructionJ Hepatobiliary Pancreat Surg20018211812311455466
   PubMedGoogle Scholar
• SukKTKimHSKimJWRisk factors for cholecystitis after metal stent placement in malignant biliary obstructionGastrointest Endosc200664452252916996343
   PubMed Web of Science ®Google Scholar
• MossACMorrisEMac MathunaPPalliative biliary stents for obstructing pancreatic carcinomaCochrane Database Syst Rev20062CD004200
   Web of Science ®Google Scholar
• PovoskiSPKarpehMSJrConlonKCBlumgartLHBrennanMFAssociation of preoperative biliary drainage with postoperative outcome following pancreaticoduodenectomyAnn Surg1999230213114210450725
   PubMed Web of Science ®Google Scholar
• SohnTAYeoCJCameronJLPittHALillemoeKDDo preoperative biliary stents increase postpancreaticoduodenectomy complications?J Gastrointest Surg200043258267 discussion 267–258.10769088
   PubMed Web of Science ®Google Scholar
• HochwaldSNBurkeECJarnaginWRFongYBlumgartLHAssociation of preoperative biliary stenting with increased postoperative infectious complications in proximal cholangiocarcinomaArch Surg1999134326126610088565
   PubMedGoogle Scholar
• MumtazKHamidSJafriWEndoscopic retrograde cholangiopan-creaticography with or without stenting in patients with pancreaticbiliary malignancy, prior to surgeryCochrane Database Syst Rev20073CD00600117636818
   PubMed Web of Science ®Google Scholar
• MallinsonCNRakeMOCockingJBChemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trialBr Med J19802816255158915917004559
   PubMed Web of Science ®Google Scholar
• KelsenDHudisCNiedzwieckiDA phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinomaCancer19916859659691833042
   PubMed Web of Science ®Google Scholar
• CullinanSMoertelCEWieandHSA phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatinCancer19906510220722122189551
   PubMed Web of Science ®Google Scholar
• FungMCIshiguroHTakayamaSMorizaneTAdachiSSakataTSurvival benefit of chemotherapy treatment in advanced pancreatic cancer: a meta-analysisProc Am Soc Clin Oncol2003221155
   Google Scholar
• GrunewaldRKantarjianHKeatingMJAbbruzzeseJTarassoffPPlunkettWPharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemiaCancer Res19905021682368262208147
   PubMed Web of Science ®Google Scholar
• TemperoMPlunkettWRuiz Van HaperenVRandomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinomaJ Clin Oncol200321183402340812885837
   PubMed Web of Science ®Google Scholar
• PoplinEFengYBerlinJPhase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology GroupJ Clin Oncol200927233778378519581537
   PubMed Web of Science ®Google Scholar
• LouvetCAndrèTLledoGGemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II studyJ Clin Oncol2002201512151811896099
   PubMed Web of Science ®Google Scholar
• LouvetCLabiancaRHammelPGemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trialJ Clin Oncol200523153509351615908661
   PubMed Web of Science ®Google Scholar
• ColucciGLabiancaRDi CostanzoFA randomized trial of gemcitabine (G) versus G plus cisplatin in chemotherapy-naive advanced pancreatic adenocarcinoma: The GIP-1 (Gruppo Italiano Pancreas – GOIM/GISCAD/GOIRC) study. 2009 ASCO Annual MeetingJ Clin Oncol200927Suppl 15 Abstract 4504.
   Google Scholar
• NietoJGrossbandMLKozuchPMetastatic pancreatic cancer 2008: is the glass less empty?Oncologist200813556257618515741
   PubMed Web of Science ®Google Scholar
• MooreMJGoldsteinDHammJErlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol2007251960196617452677
   PubMed Web of Science ®Google Scholar
• HeinemannVBoeckSHinkeALabiancaRLouvetCMeta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancerBMC Cancer200888218373843
   PubMed Web of Science ®Google Scholar
• HeinemannVLabiancaRHinkeALouvetCIncreased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter studyAnn Oncol200718101652165917660491
   PubMed Web of Science ®Google Scholar
• WangXNiQJinMGemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancerZhonghua Zhong Liu Za Zhi200224440440712408777
   PubMedGoogle Scholar
• ColucciGGiulianiFGebbiaVGemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell’Italia MeridionaleCancer200294490291011920457
   PubMed Web of Science ®Google Scholar
• Xie deRLiangHLWangYGuoSSMeta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine aloneChin J Dig Dis200671495416412038
   PubMedGoogle Scholar
• CartwrightTHCohnAVarkeyJAPhase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancerJ Clin Oncol20022016016411773165
   PubMed Web of Science ®Google Scholar
• HerrmannRBodokgGRuhstallerTGemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupJ Clin Oncol200725162212221717538165
   PubMed Web of Science ®Google Scholar
• XiongHQRosenbergALoBuglioACetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trialJ Clin Oncol200422132610261615226328
   PubMed Web of Science ®Google Scholar
• OettleHPetzerUStielerJOxaliplatin/Folinic acid/5-fluoroouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO-003)Proc Am Soc Clin Oncol2005 Abstract 4031.
   Google Scholar
• StrimpakosASaifMWSyrigosKNPancreatic cancer: from molecular pathogenesis to targeted therapyCancer Metastasis Rev200827349552218427734
   PubMed Web of Science ®Google Scholar
• IannittiDDipetrilloTAkemanPErlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: A phase I studyAm J Clin Oncol20052857057516317266
   PubMed Web of Science ®Google Scholar
• EpelbaumRSchnaiderJGluzmanAErlotinib as a single-agent therapy in patients with advanced pancreatic cancerPresented at: the ASCO Gastrointestinal Cancer symposium2007Orlando, Florida
   Google Scholar
• KulkeMHBlaszkowskyLSRyanDPCapecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancerJ Clin Oncol200725304787479217947726
   PubMed Web of Science ®Google Scholar
• PhilipPAMooneyMJaffeDConsensus report of the National Cancer Institute clinical trials planning meeting on pancreas cancer treatmentJ Clin Oncol200927335660566919858397
   PubMed Web of Science ®Google Scholar
• BurtnessBAPowellMBerlinJPhase II trial of irinotecan/docetaxel for advanced pancreatic cancer with randomization between irinotecan/docetaxel and irinotecan/docetaxel plus C225, a monoclonal antibody to the epidermal growth factor receptor (EGF-r) : Eastern Cooperative Oncology [Meeting Abstracts]J Clin Oncol200725Suppl 18451917925545
   PubMed Web of Science ®Google Scholar
• KindlerHLFribergGSinghDAPhase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancerJ Clin Oncol200523318033804016258101
   PubMed Web of Science ®Google Scholar
• KindlerHLNiedzwieckiDHollisDA double-blind, placebo controlled randomized phase III gemcitabine + bevacisumab versus gemcitabien versus placeboJ Clin Oncol200725185450817906219
   PubMed Web of Science ®Google Scholar
• WallaceJALockerGNattamSSorafenib plus gemcitabine for advanced pancreatic cancer: a phase II trial of the University of Chicago phase II consortiumJ Clin Oncol200725S 224
   Google Scholar
• O’ReillyEMNiedzwieckiDHollisDRA phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603ASCO Annual Meeting2008
   Google Scholar
• BruneKHongSMLiAGenetic and epigenetic alterations of familial pancreatic cancersCancer Epidemiol Biomarkers Prev200817123536354219064568
   PubMed Web of Science ®Google Scholar
• PietrasKRubinKSjoblomTInhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapyCancer Res200262195476548412359756
   PubMed Web of Science ®Google Scholar
• MantoniTSSchendelRRRödelFStromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinomaCancer Biol Ther2008711 [Epub ahead of print].
   Web of Science ®Google Scholar
• HwangRFMooreTArumugamTCancer-associated stromal fibroblasts promote pancreatic tumor progressionCancer Res200868391892618245495
   PubMed Web of Science ®Google Scholar
• Von HoffDDRamanathanRBoradMSPARC correlation with response to gemcitabine (G) plus nab-paclitaxel (nab-P) in patients with advanced metastatic pancreatic cancer: A phase I/II study. ASCO Annual MeetingJ Clin Oncol200927Suppl 15 Abstract 4525.
   Web of Science ®Google Scholar
• MaitraANab-paclitaxel targets tumor stroma and results, combined with gemcitabine, in high efficacy against pancreatic cancer modelsAACR20091117C246
   Google Scholar
• MaréchalRMackayJRLaiRHuman equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinomaClin Cancer Res20091582913291919318496
   PubMed Web of Science ®Google Scholar
• BergmanAMAdemaABalzariniJAntiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor modelsInvest New Drugs2010112 [Epub ahead of print].
   Google Scholar
• PecherGHaringAKaiserLThielEMucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trialCancer Immunol Immunother20025111–1266967312439613
   PubMed Web of Science ®Google Scholar
• HechtJRBedfordRAbbruzzeseJLA phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinomaClin Cancer Res20039255556112576418
   PubMed Web of Science ®Google Scholar
• WobserMKeikavoussiPKunzmannVWeiningerMAndersenMHBeckerJCComplete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivinCancer Immunol Immunother200655101294129816315030
   PubMed Web of Science ®Google Scholar
• MiyazawaMOhsawaRTsunodaTPhase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancerCancer Sci2010101243343919930156
   PubMed Web of Science ®Google Scholar
• YangASMonkenCELattimeECIntratumoral vaccination with vaccinia-expressed tumor antigen and granulocyte macrophage colony-stimulating factor overcomes immunological ignorance to tumor antigenCancer Res200363206956696114583497
   PubMed Web of Science ®Google Scholar
• JemalASiegelRWardECancer statistics, CACancer J Clin20085827196
   PubMed Web of Science ®Google Scholar
• BudihartoTHaustermansKVan CutsemEA phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinomaRadiat Oncol200833018808686
   PubMed Web of Science ®Google Scholar
• CraneCHAJEvansDBIs the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?Int J Radiat Oncol Biol Phys20025251293130211955742
   PubMed Web of Science ®Google Scholar
• McGinnCJZalupskiMMRadiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trialsInt J Radiat Oncol Biol Phys200356Suppl 4S10S15
   Web of Science ®Google Scholar
• TaberneroJMacarullaTChanging the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical developmentJ Clin Oncol200927335487549119858387
   PubMed Web of Science ®Google Scholar
• Rocha LimaCMGreenMRRotcheRIrinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rateJ Clin Oncol200422183776378315365074
   PubMed Web of Science ®Google Scholar
• HashimotoKUenoHIkedaMDo recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?Oncology2009773–421722319729980
   PubMed Web of Science ®Google Scholar
• BakkevoldKEArnesjoBDahlOKambestadBAdjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre studyEur J Cancer199329A56987038471327
   PubMed Web of Science ®Google Scholar
• YeungRSWeeseJLHoffmanJPNeoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II studyCancer1993727212421338374871
   PubMed Web of Science ®Google Scholar
• KamthanAGMorrisJCDaltonJCombined modality therapy for stage II and stage III pancreatic carcinomaJ Clin Oncol1997158292029279256136
   PubMed Web of Science ®Google Scholar
• WhiteRLeeCAnscherMPreoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreasAnn Surg Oncol199961384510030414
   PubMed Web of Science ®Google Scholar
• BajettaEDi BartolomeoMStaniSCChemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility studyInt J Radiat Oncol Biol Phys199945228528910487547
   PubMed Web of Science ®Google Scholar
• WaneboHJGlicksmanASVezeridisMPPreoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancerArch Surg20001351818710636353
   PubMed Web of Science ®Google Scholar
• KimHJCzischkeKBrennanMFConlonKCDoes neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?J Gastrointest Surg20026576376912399067
   PubMed Web of Science ®Google Scholar
• RauHGWichmannMWWilkowskiRSurgical therapy of locally advanced and primary inoperable pancreatic carcinoma after neoadjuvant preoperative radiochemotherapyChirurg200273213213711974476
   PubMed Web of Science ®Google Scholar
• AristuJCanonRPardoFSurgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancerAm J Clin Oncol2003261303612576921
   PubMed Web of Science ®Google Scholar
• WilkowskiRThomaMSchauerRWagnerAHeinemannVEffect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancerWorld J Surg10200428101011101815573257
   PubMed Web of Science ®Google Scholar
• Sa CunhaARaultALaurentCAdhouteXVendrelyVBéllannéeGBrunetRColletDMassonBSurgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreasJ Am Coll Surg2005201335936516125068
   PubMed Web of Science ®Google Scholar
• DelperoJRTurriniOLocally advanced pancreatic adenocarcinoma. Chemoradiotherapy, reevaluation and secondary resectionCancer Radiother2006106–746247016987678
   PubMedGoogle Scholar
• AdhouteXSmithDVendrelyVSubsequent resection of locally advanced pancreatic carcinoma after chemoradiotherapyGastroenterol Clin Biol200630222423016565654
   PubMedGoogle Scholar
• TinklDGrabenbauerGGGolcherHDownstaging of pancreatic carcinoma after neoadjuvant chemoradiationStrahlenther Onkol2009185557–6655756619756421
   PubMed Web of Science ®Google Scholar
• BerlinJDCatalanoPThomasJPKuglerJWHallerDGBensonABIIIPhase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297J Clin Oncol200220153270327512149301
   PubMed Web of Science ®Google Scholar
• ReissHHelmANiedergethmannMSchmidt-WolfIMoikMHammerCA randomized, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs gemcitabine in patients with advanced pancreatic cancer. ASCO Annual MeetingJ Clin Oncol200523Suppl 16 Abstract LBA4009.
   Google Scholar
• CunninghamDChauIStockenDDPhase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancerJ Clin Oncol200927335513551819858379
   PubMed Web of Science ®Google Scholar
• HeinemannVQuietzschDGieselerFRandomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancerJ Clin Oncol2006242439463952
   Web of Science ®Google Scholar
• StathopoulosGPSyrigosKAravantinosGA multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancerBr J Cancer200695558759216909140
   PubMed Web of Science ®Google Scholar
• Abou-AlfaGKLetourneauRHarkerGRandomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancerJ Clin Oncol200624274441444716983112
   PubMed Web of Science ®Google Scholar
• ReniMCordioSMilandriCGemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trialLancet Oncol20056636937615925814
   PubMed Web of Science ®Google Scholar
• OettleHRichardsDRamanathanRKA phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancerAnn Oncol200516101639164516087696
   PubMed Web of Science ®Google Scholar
• BramhallSRRosemurgyABrownPDBowryCBuckelsJAMarimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trialJ Clin Oncol200119153447345511481349
   PubMed Web of Science ®Google Scholar
• BramhallSRSchultzJNemunaitisJBrownPDBailletMBuckelsJAA double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancerBr J Cancer200287216116712107836
   PubMed Web of Science ®Google Scholar
• MooreMJHammJDanceyJComparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials GroupJ Clin Oncol200321173296330212947065
   PubMed Web of Science ®Google Scholar
• Van CutsemEvandeVeldeKarasekPPhase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancerJ Clin Oncol20042281430143815084616
   PubMed Web of Science ®Google Scholar